21,872 Shares in Tango Therapeutics, Inc. $TNGX Purchased by Mitsubishi UFJ Asset Management Co. Ltd.

Posted by Francis Steltz on May 14th, 2026

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) during the 4th quarter, HoldingsChannel reports. The firm acquired 21,872 shares of the company’s stock, valued at approximately $195,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of TNGX. Dynamic Technology Lab Private Ltd grew its position in Tango Therapeutics by 139.7% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after purchasing an additional 15,037 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Tango Therapeutics by 30.7% in the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after acquiring an additional 1,640 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Tango Therapeutics by 148,800.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock worth $40,000 after buying an additional 4,464 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Tango Therapeutics by 44.3% during the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock worth $49,000 after buying an additional 2,907 shares in the last quarter. Finally, Northeast Financial Consultants Inc bought a new stake in Tango Therapeutics during the second quarter worth approximately $51,000. Institutional investors own 78.99% of the company’s stock.

Insider Transactions at Tango Therapeutics

In related news, insider Adam Crystal sold 54,345 shares of Tango Therapeutics stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $12.77, for a total transaction of $693,985.65. Following the completion of the transaction, the insider directly owned 132,873 shares of the company’s stock, valued at $1,696,788.21. This trade represents a 29.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 179,056 shares of company stock worth $3,346,181. Company insiders own 6.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TNGX. Wedbush upped their price target on shares of Tango Therapeutics from $15.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday, March 6th. Stifel Nicolaus increased their target price on shares of Tango Therapeutics from $24.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Weiss Ratings upgraded shares of Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Citigroup restated a “buy” rating on shares of Tango Therapeutics in a report on Monday, April 27th. Finally, Canaccord Genuity Group assumed coverage on shares of Tango Therapeutics in a research report on Thursday, April 2nd. They set a “buy” rating and a $30.00 target price for the company. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.44.

Read Our Latest Stock Report on TNGX

Tango Therapeutics Stock Performance

Shares of Tango Therapeutics stock opened at $25.51 on Thursday. The firm’s 50-day simple moving average is $21.14 and its 200-day simple moving average is $14.07. Tango Therapeutics, Inc. has a twelve month low of $1.25 and a twelve month high of $28.41. The firm has a market cap of $3.68 billion, a P/E ratio of -29.32 and a beta of 1.22.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, meeting the consensus estimate of ($0.32). Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. On average, equities analysts forecast that Tango Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

About Tango Therapeutics

(Free Report)

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.

Want to see what other hedge funds are holding TNGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report).

Institutional Ownership by Quarter for Tango Therapeutics (NASDAQ:TNGX)

Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.